Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.38 |
| ▸ | LCK | P06239 | 6/20 | 0.34 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.34 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | LEF1 | Q9UJU2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3418695 | 0.95 | GSK3B (0.42) | GSK3BDYRK1AATRLCKRPS6KA3 | |
| SCHEMBL2390936 | 0.88 | GSK3B (0.40) | GSK3BDYRK1ALCKRPS6KA2IRAK4 | |
| SCHEMBL2389887 | 0.88 | GSK3B (0.40) | GSK3BDYRK1ALCKRPS6KA2IRAK4 | |
| SCHEMBL2390274 | 0.88 | RPS6KA3 (0.45) | GSK3BDYRK1ALCKRPS6KA3 | |
| SCHEMBL2389890 | 0.88 | RPS6KA3 (0.45) | GSK3BDYRK1ALCKRPS6KA3 | |
| SCHEMBL15428461 | 0.86 | HDAC1 (0.40) | GSK3BDYRK1AATRLCKRPS6KA2 | |
| SCHEMBL13879836 | 0.86 | GSK3B (0.35) | GSK3BDYRK1AATRLCKRPS6KA2 | |
| SCHEMBL18574433 | 0.86 | NAMPT (0.45) | LCKNAMPT | |
| SCHEMBL6428501 | 0.85 | GSK3B (0.41) | GSK3BDYRK1AATRLCKRPS6KA2 | |
| SCHEMBL3417370 | 0.85 | HDAC1 (0.39) | GSK3BDYRK1AATRLCKRPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-05-18 | — | — | US | disclosed |
| US-11505617-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-108727407-B | Novel benzodiazepine derivatives | 伊缪诺金公司 | 2022-01-28 | — | — | CN | disclosed |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2021-08-05 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947315-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| CN-105198908-B | Novel benzodiazepine derivatives | 伊缪诺金公司 | 2019-12-24 | — | — | CN | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN, INC. | 2019-09-12 | — | — | US | disclosed |
| US-8426402-B2 | Benzodiazepine derivatives | IMMUNOGEN, INC. (US) | 2013-04-23 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | IMMUNOGEN INC. (US) | 2010-08-12 | — | — | US | disclosed |
| US-6924396-B2 | α-haloenamine reagents | PHARMACIA CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1430028-A2 | AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES | Pharmacia Corporation (US) | 2004-06-23 | — | — | EP | disclosed |
| US-20040092770-A1 | Alpha-haloenamine reagents | PHARMACIA CORPORATION | 2004-05-13 | — | — | US | disclosed |
| US-20030105279-A1 | Aromatic and heteroaromatic acid halides for synthesizing polyamides | PHARMACIA CORPORATION | 2003-06-05 | — | — | US | disclosed |
| US-20030080320-A1 | Alpha- haloenamine reagents | PHARMACIA CORPORATION | 2003-05-01 | — | — | US | disclosed |
| WO-2003018552-A2 | AROMATIC AND HETEROAROMATIC ACID HALIDES FOR SYNTHESIZING POLYAMIDES | PHARMACIA CORPORATION (US) | 2003-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238301-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | GSK3B 193/4885DYRK1A 2155/4885ATR 3258/4885 |
| US-20230149550-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DMPK, DTYMK, MYCBP | GSK3B 2915/4885DYRK1A 3132/4885ATR 2972/4885 |
| US-20190276552-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | GSK3B 193/4885DYRK1A 2155/4885ATR 3258/4885 |
| US-20030080320-A1 | Alpha- haloenamine reagents | HNMT, HDHD5, NISCH | GSK3B 2745/4885DYRK1A 1290/4885ATR 4102/4885 |
| US-20100203007-A1 | NOVEL BENZODIAZEPINE DERIVATIVES | GABRB1, GABRB3, GABRA1 | GSK3B 193/4885DYRK1A 2155/4885ATR 3258/4885 |
| US-20040092770-A1 | Alpha-haloenamine reagents | HNMT, HDHD5, NISCH | GSK3B 2745/4885DYRK1A 1290/4885ATR 4102/4885 |
| US-11505617-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | GSK3B 102/4885DYRK1A 1900/4885ATR 3171/4885 |
| US-20030105279-A1 | Aromatic and heteroaromatic acid halides for synthesizing polyamides | AAAS, HTT, HRH4 | GSK3B 4778/4885DYRK1A 548/4885ATR 1699/4885 |
| US-10947315-B2 | Benzodiazepine derivatives | GABBR1, GABRB1, GABRA1 | GSK3B 102/4885DYRK1A 1900/4885ATR 3171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.